1. Home
  2. ICUI vs CNTA Comparison

ICUI vs CNTA Comparison

Compare ICUI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$142.61

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Logo Centessa Pharmaceuticals plc

CNTA

Centessa Pharmaceuticals plc

HOLD

Current Price

$25.05

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICUI
CNTA
Founded
1984
2020
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.7B
IPO Year
1992
2021

Fundamental Metrics

Financial Performance
Metric
ICUI
CNTA
Price
$142.61
$25.05
Analyst Decision
Buy
Strong Buy
Analyst Count
5
11
Target Price
$179.50
$37.70
AVG Volume (30 Days)
213.6K
1.2M
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,320,363,000.00
$15,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
118.88
52 Week Low
$107.00
$9.60
52 Week High
$175.51
$30.58

Technical Indicators

Market Signals
Indicator
ICUI
CNTA
Relative Strength Index (RSI) 47.09 41.94
Support Level $146.11 $24.17
Resistance Level $149.00 $26.01
Average True Range (ATR) 3.45 1.14
MACD -0.95 -0.26
Stochastic Oscillator 31.01 18.64

Price Performance

Historical Comparison
ICUI
CNTA

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

About CNTA Centessa Pharmaceuticals plc

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.

Share on Social Networks: